Cypress rebuffs sweetened offer from Ramius; BSD Medical Announces Success in Initial Product Launch. Print E-mail
By Staff   
Tuesday, 14 December 2010 20:59

Below is a look at some of the headlines for companies that made news in the healthcare sector on December 14, 2010.

Cypress Bioscience Inc (NASDAQ:CYPB) rejected a $6-per-share cash offer to acquire the drugmaker, which is in talks with a third party, according to Ramius LLC. As part of the talks, Ramius raised its offer by 9 percent after entering into negotiations with the company before going directly to the Cypress shareholders again.  Ramius, the biggest shareholder in the company, asked Cypress not to agree to any break-up fee with the other party.

Cypress shares, which have gained 38 percent in the last 3 months, were up 15 percent at $5.51 on Tuesday on Nasdaq.

BSD Medical Corporation (NASDAQ:BSDM) announced a successful product launch for the MicroThermX Microwave Ablation System (MTX-180) which focuses on placement of a select number of systems with pivotal, high-profile, interventional oncology.  Three of these systems will has been successfully placed with a fourth one coming shortly.

James G. Carlisle, M.D., an interventional oncologist, stated, “BSD has hit the ball out of the park. The MicroThermX Microwave Ablation System provides multiple benefits, including quick set-up time, ease of use, and a big reduction in footprint, with the ablation zones are large and predictable.”

Also Tuesday:

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today presented a Comprehensive R&D review and its strategic outlook for 2011, at the InterContinental New York Barclay Hotel in New York City.

Amarillo Biosciences, Inc. (ABI) (OTCBB:AMAR) today announced that enrollment in a Phase 2 clinical trial of 165 patients with chronic hepatitis C virus infection is now complete.

AmbiCom Holdings, Inc. (OTCBB: ABHI), a leader in the development of wireless products for medical equipment suppliers, today announced that it has entered into a definitive agreement to acquire 100% of E-Care Technology Co., Ltd., a Taiwan Corporation.

Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, has selected the Merck BioManufacturing Network in the UK, to manufacture the large scale GMP clinical and pre-commercial supplies of A-623, an investigational novel peptibody in development for a number of autoimmune diseases.

Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM), has entered into a binding agreement with Shandong Daxin Microbiology Pharmaceutical Industry Co., Ltd. to acquire the rights to 14 approved TCM medicines that were previously issued to Daxin by the Shandong Branch of the State Food and Drug Administration of China ("SFDA").

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX) ("Connectyx"),, manufacturer and distributor of MedFlash®, the nation's premier Personal Health Management System (PHM) for maintaining personal health records (PHR).

Elysium Internet, Inc. DBA (PINKSHEETS: EYSM) today announced that it has completed a tentative schedule to present its industry leading patient acquisition program at ten industry events across the United States.

GeckoSystems Intl. Corp. (PINKSHEETS:GOSY) announced today that their sensor fusion system, GeckoOrient™, had been significantly cost reduced while maintaining prior performance and reliability levels.

Global NuTech, Inc. (OTCBB: BOCL) ( announced today that its Joint Venture withAgrigenic Food Company, had a 40% increase in sales in October and November versus the quarter ended September 30, 2010, the end of which quarter coincided with the formation of the Joint Venture between Agrigenic Food Company and Global NuTech's wholly owned subsidiary, E-Clean Acquisition Corporation.

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today named industry veteran Rita V. Jacob Vice President for Training and Clinical Affairs, effective immediately.

Herborium Group, Inc., (PINKSHEETS:HBRM), a Botanical Therapeutics™ company, today announced that it has started selling AcnEase®, its unique botanical acne and Rosacea treatment, on

Healthnostics, Inc. (PINKSHEETS: HNS) increased its earnings guidance for the year ending December 31, 2010.

Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced that it has repaid all amounts outstanding under the Company's Facility Agreement with Deerfield Partners, entered into in March 2009.

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  

Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) announced today having now reached debt free status, and currently planning its distribution program for 2011.

Ohr Pharmaceutical Inc. (OTCBB: OHRP) today announced the enrollment of the first three patients at a new clinical site in its ongoing Phase 2b clinical trial to investigate the efficacy of OHR/AVR118 for the treatment of cancer cachexia in patients with recurrent or advanced cancers.

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne suite of applications has been chosen by a Major Pharmaceutical company to automate their clinical trial operations and processes within their early-phase (phase I, BA-BE/PK-PD and Phase IIa) clinic.

Talecris Biotherapeutics Holdings Inc. (Nasdaq:TLCR) announced today that a jury in the General Court of Justice, Superior Court Division, Wake County, North Carolina, rendered a verdict on December 13, 2010 in the amount of $37 million in favor of Plasma Centers of America, LLC, against its subsidiary, Talecris Plasma Resources, Inc., in a breach of contract claim.

Verenium Corporation (Nasdaq:VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced key 2010 accomplishments and 2011 Company goals and financial guidance.

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB:VCRT), today announced that the Company's newly-developed independent sales force is generating sales of its PD2i Analyzer™ in North Carolina, California, Texas, Michigan, Wisconsin, and Maryland.

VIVUS, Inc. (Nasdaq:VVUS) today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010.

YM BioSciences Inc. (NYSE Amex:YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that it has priced an underwritten public offering of 25,000,000 common shares at a price to the public of $1.60 per share.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus